tumor tissues; adjacent tissues
MCF-7; MDA-MB-468; MDA-MB-231; HTB126; SK-BR-3; MCF-10A; HaCaT; 293T; BEAS2B; Jurkat; HUVEC; H460; LnCap; Du145; PC3; JHH1; SNU449; HepG2; Hela
cell line-derived xenograft
autophagy (promotes); proliferation (promotes); mRNA stability (promotes); other pathway/process (inhibits)
Microarray; RT-qPCR; Clinical Sample Validation; RNase R Treatment; Northern Blot; Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; Transfection; Western Blot; IF (Immunofluorescence); Nuclear-Cytoplasmic Fractionation; RIP (RNA Immunoprecipitation); RNA Pull-Down; ISH (In Situ Hybridization); IHC (Immunohistochemistry); In Vivo Animal Model; Survival Analysis; Bioinformatics Analysis
circ-Dnmt1 is significantly upregulated in breast carcinoma patient tumors compared with adjacent tissues and is described as an oncogenic circular RNA with potential for further preclinical research.
circ-Dnmt1 is upregulated in breast cancer cell lines and breast carcinoma tumors. It functions as an oncogenic circRNA by binding p53 and AUF1/Auf1, promoting their nuclear translocation, enhancing autophagy, increasing Dnmt1 expression, inhibiting p53 transcription, reducing senescence, and promoting proliferation, survival, and xenograft tumor growth.
0.8779
A circular RNA circ-DNMT1 enhances breast cancer progression by activating autophagy.
combined biological and clinical study